No Data
Xiaofang Pharmaceutical (603207.SH): The company does not produce snake medicine.
On September 9, Gelonghui reported that Xiaofang Pharmaceutical (603207.SH) stated on the interactive platform that the company does not have snake medicine.
Chinese Shares Hold Steady Ahead of Manufacturing Data; Xiaofang Pharmaceutical Soars 167% on Debut
Shanghai Xiaofang Pharmaceutical Lists on Shanghai Bourse After 499-Million-Yuan IPO
Xiaofang Pharmaceutical (603207.SH): The stock will be listed on the main board of the Shanghai Stock Exchange on August 26th.
Gelonghui August 22nd| Xiaofang Pharmaceutical (603207.SH) announced that the company's stocks will be listed on the main board of the Shanghai Stock Exchange on August 26, 2024.
Xiaofang Pharmaceuticals (603207.SH): The final online subscription rate is 0.0478%.
On August 15, Gelunhui reported that Xiaofang Pharmaceuticals (603207.SH) announced that after the callback mechanism was initiated, the final number of shares issued to offline investors was 8 million, accounting for 20.00% of the total issued shares, while the final number of shares issued to online investors was 32 million, accounting for 80.00% of the total issued shares. After the callback mechanism was initiated, the final winning rate for online issuance was 0.04782820%.
A Share Subscription | Xiao Fang Pharmaceutical (603207.SH) started the subscription. The brand has various external use products such as Kaisailu and Lugen Stone lotion.
On August 15th, Xiaofang Pharmaceuticals (603207.SH) began its subscription.
No Data
No Data